Yi-Bo Gao

List of Publications by Year
in descending order

72 papers	3,236 citations	257101 24 h-index	161609 54 g-index
77 all docs	77 docs citations	77 times ranked	5244 citing authors

#	Article	IF	Citations
1	Plasma extracellular vesicle microRNA profiling and the identification of a diagnostic signature for stage I lung adenocarcinoma. Cancer Science, 2022, 113, 648-659.	1.7	16
2	Multimodality Treatment of Pulmonary Sarcomatoid Carcinoma: A Review of Current State of Art. Journal of Oncology, 2022, 2022, 1-11.	0.6	6
3	Choline Kinase Alpha2 Promotes Lipid Droplet Lipolysis in Non-Small-Cell Lung Carcinoma. Frontiers in Oncology, 2022, 12, 848483.	1.3	1
4	A Complement-Related Gene Signature for Predicting Overall Survival and Immunotherapy Efficacy in Sarcoma Patients. Frontiers in Cell and Developmental Biology, 2022, 10, 765062.	1.8	2
5	Sintilimab for the treatment of non-small cell lung cancer. Biomarker Research, 2022, 10, 23.	2.8	16
6	Association of phosphoenolpyruvate carboxykinase 1 protein kinase activity-dependent sterol regulatory element-binding protein 1 activation with prognosis of oesophageal carcinoma. European Journal of Cancer, 2021, 142, 123-131.	1.3	11
7	Prognostic immunohistochemical markers for small cell lung cancer: A review. Pathology Research and Practice, 2021, 217, 153311.	1.0	2
8	MiRACLe: an individual-specific approach to improve microRNA-target prediction based on a random contact model. Briefings in Bioinformatics, 2021, 22, .	3.2	1
9	Prognostic Impact of PCK1 Protein Kinase Activity-Dependent Nuclear SREBP1 Activation in Non-Small-Cell Lung Carcinoma. Frontiers in Oncology, 2021, 11, 561247.	1.3	13
10	Comprehensive Analysis of Ferroptosis Regulators in Lung Adenocarcinomas Identifies Prognostic and Immunotherapy-Related Biomarkers. Frontiers in Molecular Biosciences, 2021, 8, 587436.	1.6	13
11	Safety and Efficacy of Neoadjuvant Immune Checkpoint Inhibitor Therapy in Patients with Resectable Non-small-Cell Lung Cancer: A Systematic Review. Targeted Oncology, 2021, 16, 425-434.	1.7	16
12	WNT/Î²-catenin-suppressed FTO expression increases m6A of c-Myc mRNA to promote tumor cell glycolysis and tumorigenesis. Cell Death and Disease, 2021, 12, 462.	2.7	75
13	Development and validation of m6A RNA methylation regulators-based signature in lung adenocarcinoma. Chinese Medical Journal, 2021, 134, 2128-2130.	0.9	3
14	Multi-omics profiling of primary small cell carcinoma of the esophagus reveals RB1 disruption and additional molecular subtypes. Nature Communications, 2021, 12, 3785.	5.8	16
15	Profiling of 520 Candidate Genes in 50 Surgically Treated Chinese Small Cell Lung Cancer Patients. Frontiers in Oncology, 2021, 11, 644434.	1.3	7
16	METTL3 promotes tumour development by decreasing APC expression mediated by APC mRNA N6-methyladenosine-dependent YTHDF binding. Nature Communications, 2021, 12, 3803.	5.8	74
17	Intensity modulated radiation therapy may improve survival for tracheal-bronchial adenoid cystic carcinoma: A retrospective study of 133 cases. Lung Cancer, 2021, 157, 116-123.	0.9	4
18	Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis. Lancet Oncology, The, 2021, 22, 1265-1274.	5.1	102

#	Article	IF	Citations
19	Ferroptosis Characterization in Lung Adenocarcinomas Reveals Prognostic Signature With Immunotherapeutic Implication. Frontiers in Cell and Developmental Biology, 2021, 9, 743724.	1.8	2
20	Comprehensive Analysis Uncovers Prognostic and Immunogenic Characteristics of Cellular Senescence for Lung Adenocarcinoma. Frontiers in Cell and Developmental Biology, 2021, 9, 780461.	1.8	28
21	Plasma extracellular vesicle long RNA profiling identifies a diagnostic signature for stage I lung adenocarcinoma. Translational Lung Cancer Research, 2021, 11, 0-0.	1.3	2
22	Cross-talk of pyroptosis and tumor immune landscape in lung adenocarcinoma. Translational Lung Cancer Research, 2021, 10, 4423-4444.	1.3	6
23	Identification and validation of cellular senescence patterns to predict clinical outcomes and immunotherapeutic responses in lung adenocarcinoma. Cancer Cell International, 2021, 21, 652.	1.8	11
24	Analysis of a registry database for esophageal cancer from high-volume centers in China. Ecological Management and Restoration, 2020, 33, .	0.2	25
25	Integrated molecular characterization reveals potential therapeutic strategies for pulmonary sarcomatoid carcinoma. Nature Communications, 2020, 11, 4878.	5.8	27
26	Prognostic value of tumor-infiltrating lymphocytes in esophageal cancer: an updated meta-analysis of 30 studies with 5,122 patients. Annals of Translational Medicine, 2020, 8, 822-822.	0.7	23
27	Monoacylglycerol Lipase Knockdown Inhibits Cell Proliferation and Metastasis in Lung Adenocarcinoma. Frontiers in Oncology, 2020, 10, 559568.	1.3	12
28	Development and validation of an immuneâ€related prognostic signature in lung adenocarcinoma. Cancer Medicine, 2020, 9, 5960-5975.	1.3	79
29	Elevated TOP2A and UBE2C expressions correlate with poor prognosis in patients with surgically resected lung adenocarcinoma: a study based on immunohistochemical analysis and bioinformatics. Journal of Cancer Research and Clinical Oncology, 2020, 146, 821-841.	1.2	22
30	Elevated SLC2A1 Expression Correlates with Poor Prognosis in Patients with Surgically Resected Lung Adenocarcinoma: A Study Based on Immunohistochemical Analysis and Bioinformatics. DNA and Cell Biology, 2020, 39, 631-644.	0.9	15
31	Loss of SUSD2 expression correlates with poor prognosis in patients with surgically resected lung adenocarcinoma. Journal of Cancer, 2020, 11, 1648-1656.	1.2	6
32	Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC. Journal of Thoracic Oncology, 2020, 15, 816-826.	0.5	272
33	Construction and Comprehensive Analyses of a METTL5-Associated Prognostic Signature With Immune Implication in Lung Adenocarcinomas. Frontiers in Genetics, 2020, 11, 617174.	1.1	12
34	Utility of isocitrate dehydrogenase 1 as a serum protein biomarker for the early detection of nonâ€smallâ€cell lung cancer: A multicenter in vitro diagnostic clinical trial. Cancer Science, 2020, 111, 1739-1749.	1.7	11
35	Systemic immune-inflammation index (SII) is useful to predict survival outcomes in patients with surgically resected esophageal squamous cell carcinoma. Journal of Cancer, 2019, 10, 3188-3196.	1.2	54
36	Tracheobronchial Adenoid Cystic Carcinoma: 50-Year Experience at the National Cancer Center, China. Annals of Thoracic Surgery, 2019, 108, 873-882.	0.7	26

#	Article	IF	Citations
37	PD-L1 and CD47 co-expression in pulmonary sarcomatoid carcinoma: a predictor of poor prognosis and potential targets of future combined immunotherapy. Journal of Cancer Research and Clinical Oncology, 2019, 145, 3055-3065.	1.2	24
38	Associations of PGK1 promoter hypomethylation and PGK1â€mediated PDHK1 phosphorylation with cancer stage and prognosis: a TCGA panâ€cancer analysis. Cancer Communications, 2019, 39, 1-17.	3.7	23
39	Knockdown of KLF5 promotes cisplatinâ€induced cell apoptosis via regulating DNA damage checkpoint proteins in nonâ€small cell lung cancer. Thoracic Cancer, 2019, 10, 1069-1077.	0.8	18
40	Prognostic Impact of Metabolism Reprogramming Markers Acetyl-CoA Synthetase 2 Phosphorylation and Ketohexokinase-A Expression in Non-Small-Cell Lung Carcinoma. Frontiers in Oncology, 2019, 9, 1123.	1.3	21
41	PD-L1 expression on tumor cells associated with favorable prognosis in surgically resected esophageal squamous cell carcinoma. Human Pathology, 2019, 84, 291-298.	1.1	18
42	Efficacy and safety of neoadjuvant PD-1 blockade with sintilimab in resectable squamous non-small cell lung cancer (sqNSCLC).. Journal of Clinical Oncology, 2019, 37, 8531-8531.	0.8	10
43	Primary and acquired EGFR T790M-mutant NSCLC patients identified by routine mutation testing show different characteristics but may both respond to osimertinib treatment. Cancer Letters, 2018, 423, 9-15.	3.2	38
44	TGF-Î²-induced NKILA inhibits ESCC cell migration and invasion through NF-ÎºB/MMP14 signaling. Journal of Molecular Medicine, 2018, 96, 301-313.	1.7	44
45	Apolipoprotein E Overexpression Is Associated With Tumor Progression and Poor Survival in Colorectal Cancer. Frontiers in Genetics, 2018, 9, 650.	1.1	45
46	GADD45B as a Prognostic and Predictive Biomarker in Stage II Colorectal Cancer. Genes, 2018, 9, 361.	1.0	45
47	Prognostic value of PD-L1 in esophageal squamous cell carcinoma: a meta-analysis. Oncotarget, 2018, 9, 13920-13933.	0.8	60
48	The high expression instead of mutation of p53 is predictive of overall survival in patients with esophageal squamousâ€cell carcinoma: a metaâ€analysis. Cancer Medicine, 2017, 6, 54-66.	1.3	15
49	Exosomes: New players in cancer. Oncology Reports, 2017, 38, 665-675.	1.2	122
50	High expression of Collagen Triple Helix Repeat Containing 1 (CTHRC1) facilitates progression of oesophageal squamous cell carcinoma through MAPK/MEK/ERK/FRA-1 activation. Journal of Experimental and Clinical Cancer Research, 2017, 36, 84.	3.5	54
51	Postoperative survival of EGFR-TKI-targeted therapy in non-small cell lung cancer patients with EGFR 19 or 21 mutations: a retrospective study. World Journal of Surgical Oncology, 2017, 15, 197.	0.8	11
52	Immunohistochemical prognostic markers of esophageal squamous cell carcinoma: a systematic review. Chinese Journal of Cancer, 2017, 36, 65.	4.9	55
53	AJUBA promotes the migration and invasion of esophageal squamous cell carcinoma cells through upregulation of MMP10 and MMP13 expression. Oncotarget, 2016, 7, 36407-36418.	0.8	35
54	Combination of platelet count and mean platelet volume (COP-MPV) predicts postoperative prognosis in both resectable early and advanced stage esophageal squamous cell cancer patients. Tumor Biology, 2016, 37, 9323-9331.	0.8	81

#	Article	IF	Citations
55	Abstract 4759: Identification of ALK, ROS1, FGFR2 and NRG1 fusions and validation with targeted inhibitors in lung and ovarian PDX models. , 2016, , .		0
56	Phosphorylation of Mutationally Introduced Tyrosine in the Activation Loop of HER2 Confers Gain-of-Function Activity. PLoS ONE, 2015, 10, e0123623.	1.1	6
57	Application of SAW gas chromatography in the early screening of lung cancer. , 2015, , .		3
58	Xerophilusin B Induces Cell Cycle Arrest and Apoptosis in Esophageal Squamous Cell Carcinoma Cells and Does Not Cause Toxicity in Nude Mice. Journal of Natural Products, 2015, 78, 10-16.	1.5	23
59	Development and validation of clinical diagnostic models for the probability of malignancy in solitary pulmonary nodules. Thoracic Cancer, 2014, 5, 162-168.	0.8	16
60	LncRNA profile study reveals a three-lncRNA signature associated with the survival of patients with oesophageal squamous cell carcinoma. Gut, 2014, 63, 1700-1710.	6.1	385
61	Low frequency of TERT promoter somatic mutation in 313 sporadic esophageal squamous cell carcinomas. International Journal of Cancer, 2014, 134, 493-494.	2.3	23
62	Genetic landscape of esophageal squamous cell carcinoma. Nature Genetics, 2014, 46, 1097-1102.	9.4	600
63	MiRNA expression profile reveals a prognostic signature for esophageal squamous cell carcinoma. Cancer Letters, 2014, 350, 34-42.	3.2	43
64	MicroRNA-99a/100 promotes apoptosis by targeting mTOR in human esophageal squamous cell carcinoma. Medical Oncology, 2013, 30, 411.	1.2	93
65	Folate Receptor-Positive Circulating Tumor Cells as a Novel Diagnostic Biomarker in Non-Small Cell Lung Cancer. Translational Oncology, 2013, 6, 697-702.	1.7	93
66	Isocitrate Dehydrogenase 1 Is a Novel Plasma Biomarker for the Diagnosis of Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2013, 19, 5136-5145.	3.2	37
67	Identification of Isocitrate Dehydrogenase 1 as a Potential Diagnostic and Prognostic Biomarker for Non-small Cell Lung Cancer by Proteomic Analysis. Molecular and Cellular Proteomics, 2012, 11, M111.008821.	2.5	52
68	MicroRNA-25 promotes cell migration and invasion in esophageal squamous cell carcinoma. Biochemical and Biophysical Research Communications, 2012, 421, 640-645.	1.0	115
69	Abstract 2351: Identification of somatic mutations in esophageal squamous cell carcinoma and corresponding xenograft by next-generation sequencing. , 2012, , .		1
70	Abstract LB-397: Deep sequencing of Xenografts and case-matched blood and primary tumors reveals a 20 folds enrichment of loss of heterozygosity versus somatic mutations suggesting LOH plays an ever important role in tumorigenesis. , 2012, , .		2
71	PGK1 Promoter Hypomethylation and PGK1-Mediated PDHK1 Phosphorylation Associate with Stage and Prognosis in Multiple Human Cancers. SSRN Electronic Journal, 0, , .	0.4	0
72	The Deubiquitinase USP13 Maintains Cancer Cell Stemness by Promoting FASN Stability in Small Cell Lung Cancer. Frontiers in Oncology, 0, 12, .	1.3	5